Provided by Tiger Trade Technology Pte. Ltd.

INmune Bio Inc

1.95
0.0000
Volume:246.62K
Turnover:475.93K
Market Cap:54.12M
PE:-2.81
High:1.97
Open:1.97
Low:1.89
Close:1.95
52wk High:2.60
52wk Low:1.09
Shares:27.75M
Float Shares:23.19M
Volume Ratio:1.56
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6937
EPS(LYR):-1.8600
ROE:-74.82%
ROA:-39.12%
PB:2.66
PE(LYR):-1.05

Loading ...

INmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application

MT Newswires Live
·
Jun 23

INmune Bio - Mhra Affirms INmune Bio's Pooled-Donor Approach as Acceptable

THOMSON REUTERS
·
Jun 23

INmune Bio: Advancing Final Commercial Manufacturing Validation Activities & Dossier Compilation to Support Planned UK Submission

THOMSON REUTERS
·
Jun 23

INmune Bio Receives Mhra Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for Cordstrom™ in Rdeb

THOMSON REUTERS
·
Jun 23

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

GlobeNewswire
·
Jun 23

INmune Bio shareholders back amended 2021 stock incentive plan, boosting share pool to 9,158,525

Reuters
·
Jun 18

INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial

TIPRANKS
·
Jun 02

INmune Bio - Xpro1595 Efficacy Strengthened in Biomarker-Enriched Patients With Elevated Inflammation

THOMSON REUTERS
·
Jun 02

INmune Bio - Xpro1595 Shows Significant Treatment Effect in Full Mitt Population

THOMSON REUTERS
·
Jun 02

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter Mri Biomarker in Phase 2 Mindful Alzheimer's Trial

THOMSON REUTERS
·
Jun 02

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

GlobeNewswire
·
Jun 02

INmune Bio publishes Phase 2 MINDFuL results for XPro in Alzheimer’s subgroup with inflammation

Reuters
·
May 15

INmune Bio Receives FDA Fast Track Designation for Xpro1595 in Early Alzheimer's Disease

THOMSON REUTERS
·
May 14

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

GlobeNewswire
·
May 14

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

GlobeNewswire
·
May 13

Analysts Have Conflicting Sentiments on These Healthcare Companies: Inmune Bio (INMB) and Joint (JYNT)

TIPRANKS
·
May 10

INmune Bio Q1 net loss narrows on lower R&D expenses

Reuters
·
May 08

INmune Bio Q1 EPS USD -0.2

THOMSON REUTERS
·
May 08

INmune Bio Q1 EPS $(0.20) Beats $(0.22) Estimate.

Benzinga Earnings
·
May 08

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update

GlobeNewswire
·
May 08